First, we estimated the effects of SGLT2 inhibition on prostate cancer prevention using genetic, electronic healthcare, and epidemiological approaches, which have different assumptions, key source of biases (e.g., pleiotropy for MR and confounders for observational analysis),11 and different subgroup of population (i.e., the general male population and males with diabetes). This evidence concerns the gene SLC5A2 and prostate carcinoma.